Journalartikel
Autorenliste: Yan, Hang; Dittmar, Florian; Schagdarsurengin, Undraga; Wagenlehner, Florian
Jahr der Veröffentlichung: 2020
Seiten: 30-37
Zeitschrift: Urology
Bandnummer: 145
ISSN: 0090-4295
eISSN: 1527-9995
DOI Link: https://doi.org/10.1016/j.urology.2020.06.039
Verlag: Elsevier
Abstract:
Circulating tumor cells (CTCs) are considered to be promising biomarkers in malignant diseases. Recently, molecular profiles of CTCs in prostate cancer (PCa) and the role of CTCs in neoadjuvant chemotherapy and transurethral resections of bladder cancer (BCa) are intensely studied. However, localized PCa and nonmuscle-invasive BCa are less investigated and discussed. Moreover, the benefit and feasibility of clinical applications of CTCs should be critically questioned and reevaluated. This review focuses mainly on clinical issues and lesser on methodologies, and summarizes the quintessence of available works dealing with clinical applications of CTCs in PCa and BCa management. (C) 2020 Elsevier Inc.
Zitierstile
Harvard-Zitierstil: Yan, H., Dittmar, F., Schagdarsurengin, U. and Wagenlehner, F. (2020) The Clinical Application and Potential Roles of Circulating Tumor Cells in Bladder Cancer and Prostate Cancer, Urology, 145, pp. 30-37. https://doi.org/10.1016/j.urology.2020.06.039
APA-Zitierstil: Yan, H., Dittmar, F., Schagdarsurengin, U., & Wagenlehner, F. (2020). The Clinical Application and Potential Roles of Circulating Tumor Cells in Bladder Cancer and Prostate Cancer. Urology. 145, 30-37. https://doi.org/10.1016/j.urology.2020.06.039
Schlagwörter
ABIRATERONE; AR-V7; CTC; HIGH-RISK; PERIPHERAL-BLOOD; PREDICT; RESECTION